Compositions and methods for diagnosing Alzheimer's disease
Abstract
The present invention provides methods and compositions for the diagnosis of Alzheimer's disease. In particular, the present invention provides modified beta-amyloid peptides, antibodies that specifically bind to the modified beta-amyloid peptides, and methods for using these compositions in the diagnosis of Alzheimer's disease, as well as methods to monitor treatment and/or disease progression of Alzheimer's disease in patients. The present invention also provides compositions and methods useful in research involving amyloid precursor protein (APP) metabolism and Alzheimer's disease.
Claims
exact text as granted — not AI-modified1 - 3 . (canceled)
4 . A purified antibody directed against a modified β-amyloid peptide comprising at least one malondialdehyde adduct.
5 . A composition comprising the antibody of claim 4 .
6 - 21 . (canceled)
22 . A kit for the detection of at least one modified β-amyloid peptide comprising at least one malondialdehyde adduct, comprising a solid support, and an antibody directed against a modified β-amyloid peptide comprising at least one malondialdehyde adduct.
23 . The kit of claim 22 , wherein said kit comprises an enzyme-linked immunosorbent assay kit.
24 . The kit of claim 23 , wherein said kit further comprises one or more components selected from the group consisting of instructions, at least one modified β-amyloid peptide comprising at least one malondialdehyde adduct, enzyme-conjugated detection antibody capture antibody, buffer, and enzyme reaction substrate.
25 - 35 . (canceled)
36 . A kit for the detection of at least one antibody directed against at least one modified β-amyloid peptide comprising at least one malondialdehyde adduct, comprising a solid support, at least one purified and modified β-amyloid peptide comprising at least one malondialdehyde adduct, and at least one detection antibody.
37 . The kit of claim 36 , wherein said kit is an enzyme-linked immunosorbent assay kit.
38 . The kit of claim 40 , wherein said kit comprises one or more components selected from the group consisting of instructions, at least one purified antibody directed against at least one β-amyloid peptide comprising at least one malondialdehyde adduct, buffer, and enzyme reaction substrate.
39 . The antibody of claim 4 , wherein said peptide comprises the amino acid sequence of SEQ ID NO:1.
40 . The antibody of claim 39 , wherein said at least one malondialdehyde adduct comprises at least one malondialdehyde lysine adduct.
41 . The antibody of claim 4 , wherein said antibody further comprises a enzyme conjugate selected from the group consisting of horseradish peroxidase, alkaline phosphatase, urease, glucoamylase, and β-galactosidase.
42 . The antibody of claim 4 , wherein said antibody is a polyclonal antibody.
43 . The kit of claim 23 , wherein said enzyme-linked immunosorbent assay is selected from the group consisting of direct enzyme-linked immunosorbent assays, indirect enzyme-linked immunosorbent assays, direct sandwich enzyme-linked immunosorbent assays, indirect sandwich enzyme-linked immunosorbent assays, and competitive enzyme-linked immunosorbent assays.
44 . The kit of claim 22 , wherein said kit comprises a western blot kit.
45 . The kit of claim 37 , wherein said enzyme-linked immunosorbent assay is selected from the group consisting of direct enzyme-linked immunosorbent assays, indirect enzyme-linked immunosorbent assays, direct sandwich enzyme-linked immunosorbent assays, indirect sandwich enzyme-linked immunosorbent assays, and competitive enzyme-linked immunosorbent assays.
46 . The kit of claim 36 , wherein said kit comprises a western blot kit.Join the waitlist — get patent alerts
Track US2005042221A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.